The urgency of the opioid crisis that began in 2019 has not abated and fentanyl continues to fuel the overdose rates. More recently, an emerging trend has been identified. Yet another dangerous substance called Xylazine has been found more frequently in various illicit substances and is worsening outcomes for people who use opioids.   

This webinar is intended to provide the latest information available on Xylazine, including associated effects on the body and long-term impacts on opioid users, and review  current organizational strategies to help prevent exacerbated and related harm.

Credits: This training meets the requirements for 1.5 renewal hours (CASAC, CPP, CPS) and 1.5 initial hours (CPP, CPS) through New York State’s Office of Addiction Services and Supports (NYS OASAS). As an IC & RC member board, OASAS accredited courses are granted reciprocal approval by the New Jersey Division of Consumer Affairs, Alcohol and Drug Counselor Committee. Many other states offer reciprocity - please check with your accrediting agency.

Participants are required to attend the session in its entirety, turn on their video cameras, and actively participate in order to receive credit.